From vaccine production to molecular biology to industrial engineering Ziccum’s Board members bring extensive expertise to the company and its business and technology development.
Jonas Ekblom
Chairman of the Board
Born: 1965
Appointed: May 29, 2024.
Qualifications: Dr. Med. Sci. in neuroscience from Uppsala University, postdoctoral training from University of Southern California, Los Angeles. Furthermore, he is Assoc. Professor in pharmacology at Uppsala University. Independent of Ziccum and of its senior management. Independent of major shareholders of Ziccum.
Experience: Jonas has over 25 years of experience in the life sciences industry. Jonas has held senior and executive management roles in biotech companies in Sweden, US, and Switzerland in Pharmacia, Biovitrum, Sequenom, and Invitrogen. Since 2008, he has held CEO positions in medical innovation companies including BOWS Pharmaceuticals SA (2008-2011), Pergamum AB (2011-2016) and Promore Pharma AB (2016-2023). Jonas has published more than 60 peer-reviewed articles.
Current roles: Chairman of the Board of CombiGene AB (publ) and Oblique Therapeutics AB (publ) and board member of Emplipharm AB and Moberg Pharma AB (publ).
Mikaela Bruhammar
Born: 1976
Appointed: May 20, 2019.
Qualifications: MSc Molecular Biology. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Mikaela has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, at the global and HQ level. During 1999-2008 she held various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). From Aug 2019 until Aug 2023 she worked at IQVIA managing Real World Evidence Solutions, operating as Vice President EMEA RW Partnerships. Her current role is COO for the Swiss-based RW-data science and technology company BC-Platforms.
Ownership: 9 000 shares and 33 000 warrants
Andreas Pettersson Rohman
Born: 1980.
Appointed: April 27, 2021.
Qualifications: MSc. and BSc. Industrial Engineering and Management, Chalmers University of Technology. MSc. Advanced Finance, School of Business, Economics and Law, Gothenburg University. BSc National Economics, School of Business, Economics and Law, Gothenburg University.
Experience: Andreas has extensive experience from strategy development as well as supportive debt and equity financing. He currently serves as Vice President Corporate Finance and Investor Relations at Northvolt and previously worked as an Investment Professional at EQT within the Private Equity business line and prior to that at Goldman Sachs International in London within the Investment Banking Division.
Ownership: 39 333 shares and 33 000 warrants
Per Gerde
Born: 1953
Appointed: May 24, 2023
Qualifications: Associate Professor of Inhalation Toxicology, Scientist at the Division of Physiology, Institute of Environmental Medicine at the Karolinska Institutet and founder of the Company. Previous appointments include scientist at the Lovelace Respiratory Research Institute (1993– 1998), scientist at the Swedish National Institute of Occupational Health (1991–1996), and postdoctoral fellow at the Lovelace Respiratory Research Institute (1989–1991). Gerde has published approx. 55 peer reviewed scientific papers. He is also the main inventor of six patent families with related patent applications.
Current roles: CSO and Board member in Inhalation Sciences Sweden AB
Ownership: 244 444 shares
Valentina Screpanti Sundquist
Born: 1972
Appointed: May 29, 2024.
Qualifications: MSc in Molecular Biology from Stockholm University, PhD in Immunology from the Wenner-Gren Institute at Stockholm University, postdoctoral training from Center for Infectious Medicine, Karolinska Institutet. Independent of Ziccum and of its senior management. Independent of major shareholders of Ziccum.
Experience: Valentina has almost 20 years of experience in the life sciences industry. Valentina has held senior and managerial roles in Swedish biotechnology companies such as BioArctic Neuroscience, Astra Zeneca, Crucell (Johnson and Johnson), and Valneva.
Current roles: Principal Scientist Technical Development at Valneva. She also represents Sweden on behalf of the Swedish Medical Products Agency in the expert group 15, human vaccines and sera, at the European Pharmacopoeia, European Directorate for the Quality of Medicines HealthCare (EDQM, Council of Europe).